Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Antigen Levels Show Prostate Cancer’s Aggressiveness

New method may help determine whether patients need surgery or not

by Stu Borman
August 26, 2013 | A version of this story appeared in Volume 91, Issue 34

The level of prostate-specific antigen (PSA) in serum is often used to diagnose prostate cancer. Some patients with high PSA levels undergo invasive biopsies or surgery, which can cause side effects like incontinence and impotence. Some prostate cancers are slow to progress, and studies have shown that some patients do better if they watch and wait instead of having surgery. Michael J. Ahrens of the biotech firm Ohmx Corp. and coworkers, including chemist Thomas J. Meade of Northwestern University, have now tested what could turn out to be an improved diagnostic procedure, and initial results are promising (Prostate 2013, DOI: 10.1002/pros.22714). The researchers propose that PSA enzymatic activity, instead of PSA concentration, be measured to assess prostate cancer’s aggressiveness. Their study of surgically treated patients finds that higher levels of PSA activity correspond with less aggressive types of prostate cancers. “Our results suggest that many—22% in our study population—of the diagnosed patients with nonaggressive prostate cancer could have averted or delayed radical prostatectomy,” the researchers note. Ohmx is continuing validation studies and developing a commercial test, which they have trademarked PPA (PSA Peptidase Activity).

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.